Drugs / RO7795081
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07499050 | Mar → Dec 2026 expected | obesity disorder | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT06982131 | Jun 2025 → Dec 2026 expected | obesity disorder | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT06809608 | Feb → Jun 2025 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT05814107 | May 2023 → Nov 2025 | obesity disorder, type 2 diabetes mellitus | Carmot Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07112872 | Aug 2025 → Nov 2026 expected | type 2 diabetes mellitus | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07081958 | Jul 2025 → Apr 2026 overdue | obesity disorder | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-07-17 | Roche Global Development | [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity roche.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7795081 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07499050 ↗ |
| Known as | CT-996 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05814107 ↗ |
| Route | Oral | “A single dose will be administered orally per study period (see arm descriptions).” NCT06809608 ↗ |